Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Gilead Sciences Inc (GILD)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (BATS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
[[ ctrl.chartTitle ]]
Full Chart

Fundamentals

See More
  • Market Capitalization, $K 104,787,824
  • Shares Outstanding, K 1,305,930
  • Annual Sales, $ 30,390 M
  • Annual Income, $ 13,501 M
  • 36-Month Beta 1.14
  • Price/Sales 3.44
  • Price/Cash Flow 6.35
  • Price/Book 4.52

Price Performance

See More
Period Period Low Period High Performance
1-Month
79.21 +1.01%
on 09/28/17
84.73 -5.57%
on 09/26/17
-2.96 (-3.57%)
since 09/18/17
3-Month
71.77 +11.48%
on 07/19/17
86.27 -7.26%
on 09/08/17
+8.32 (+11.61%)
since 07/18/17
52-Week
63.76 +25.49%
on 06/16/17
86.27 -7.26%
on 09/08/17
+6.60 (+8.99%)
since 10/18/16

Most Recent Stories

More News
Kite's Yescarta(TM) (Axicabtagene Ciloleucel) Becomes First CAR T Therapy Approved by the FDA for the Treatment of Adult Patients With Relapsed or Refractory Large B-Cell Lymphoma After Two or More Lines of Systemic Therapy

Kite, a Gilead Company, (Nasdaq: GILD) today announced that the U.S. Food and Drug Administration (FDA) has granted regular approval to Yescarta(TM) (axicabtagene ciloleucel), the first chimeric...

GILD : 80.01 (-0.29%)
Top Stock Reports for IBM, Celgene and Procter & Gamble

Top Stock Reports for IBM, Celgene and Procter & Gamble

CELG : 137.17 (-1.22%)
S : 7.05 (-0.56%)
IBM : 159.53 (+8.86%)
PG : 92.77 (-0.03%)
VLO : 77.62 (unch)
GILD : 80.01 (-0.29%)
Where to Find Value in Healthcare Stocks

The Biotech stocks have been on a big run in 2017, but that doesn't mean there aren't some healthcare values still out there.

AET : 157.43 (+0.98%)
ABBV : 96.04 (+4.20%)
GILD : 80.01 (-0.29%)
TEVA : 14.62 (-0.81%)
BIIB : 344.58 (+0.03%)
Innovative Pipelines & Regulatory Catalysts to Drive Pharma Stocks

Innovative Pipelines & Regulatory Catalysts to Drive Pharma Stocks

LGND : 144.16 (+1.41%)
CELG : 137.17 (-1.22%)
NVO : 50.13 (+1.66%)
VRTX : 154.76 (-0.19%)
NVS : 86.04 (-0.35%)
GILD : 80.01 (-0.29%)
PFE : 35.83 (-1.02%)
Zacks Industry Outlook Highlights: Gilead, Teva, Pfizer and Amgen

Zacks Industry Outlook Highlights: Gilead, Teva, Pfizer and Amgen

GILD : 80.01 (-0.29%)
TEVA : 14.62 (-0.81%)
AMGN : 186.28 (+0.05%)
PFE : 35.83 (-1.02%)
Today's Research Reports on Stocks to Watch: Allergan and Gilead Sciences

NEW YORK, NY / ACCESSWIRE / October 17, 2017 / Shares of Allergan closed lower after a federal judge invalidated four of the company's patents for its eye-drug Restasis. Shares of Gilead also went lower...

AGN : 187.15 (-5.37%)
GILD : 80.01 (-0.29%)
Gilead Sciences Announces Promotion of Alessandro Riva to Executive Vice President, Oncology Therapeutics

Gilead Sciences, Inc. (Nasdaq: GILD) announced today the promotion of Alessandro Riva, MD, to Executive Vice President, Oncology Therapeutics, with responsibility for Gilead's hematology...

GILD : 80.01 (-0.29%)
KITE : 179.99 (+0.11%)
Pharma Industry Outlook - October 2017

Pharma Industry Outlook - October 2017

TEVA : 14.62 (-0.81%)
GILD : 80.01 (-0.29%)
AMGN : 186.28 (+0.05%)
PFE : 35.83 (-1.02%)
The Zacks Analyst Blog Highlights: NIKE, Cisco Systems, Gilead Sciences, Las Vegas Sands and Aon

The Zacks Analyst Blog Highlights: NIKE, Cisco Systems, Gilead Sciences, Las Vegas Sands and Aon

AON : 149.60 (+0.27%)
CSCO : 33.55 (-0.15%)
LVS : 61.89 (-0.67%)
NKE : 52.30 (+0.58%)
GILD : 80.01 (-0.29%)
Gilead Awards $7.5 Million in Second Round of Grants to Advance HIV Cure Research

Gilead Sciences, Inc. (NASDAQ:GILD) today announced the second round of recipients of its HIV cure grants program. This new commitment will provide $7.5 million to support five additional...

GILD : 80.01 (-0.29%)

Barchart Technical Opinion

The Barchart Opinion rating is a Hold. Short term, the outlook is Falling.

See More

Business Summary

Gilead Sciences, Inc. is an independent biopharmaceutical company that seeks to provide accelerated solutions for patients and the people who care for them. They have a broad-based focus on developing and marketing drugs to treat patients with infectious diseases, including viral infections, fungal infections...

See More

Support & Resistance

2nd Resistance Point 81.28
1st Resistance Point 80.65
Last Price 80.01
1st Support Level 79.57
2nd Support Level 79.12

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart